Predictive Oncology Inc. (POAI)
USD 0.73
(-1.35%)
USD 0.73
(-1.35%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -13.18 Million USD | -298.93% |
| 2022 | -13.95 Million USD | 50.53% |
| 2021 | -12.13 Million USD | -1962.73% |
| 2020 | -11.45 Million USD | 107.31% |
| 2019 | -12.41 Million USD | 36.42% |
| 2018 | -7.71 Million USD | -0.5% |
| 2017 | -5.98 Million USD | -19.11% |
| 2016 | -6.44 Million USD | -49.12% |
| 2015 | -4.32 Million USD | 32.53% |
| 2014 | -6.39 Million USD | 27.05% |
| 2013 | -8.76 Million USD | -22.63% |
| 2012 | -7.16 Million USD | -74.51% |
| 2011 | -4.25 Million USD | -240.95% |
| 2010 | -1.2 Million USD | 41.9% |
| 2009 | -2.81 Million USD | -23.81% |
| 2008 | -1.67 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -3.02 Million USD | 25.75% |
| 2024 Q1 | -4.07 Million USD | -21.71% |
| 2023 Q1 | -3.22 Million USD | -467.01% |
| 2023 Q4 | -3.34 Million USD | -11.79% |
| 2023 Q3 | -2.99 Million USD | 13.47% |
| 2023 Q2 | -3.46 Million USD | -7.2% |
| 2023 FY | - USD | -298.93% |
| 2022 Q3 | -3.81 Million USD | -191.43% |
| 2022 Q2 | 4.16 Million USD | 234.76% |
| 2022 FY | - USD | 50.53% |
| 2022 Q1 | -3.09 Million USD | -738.85% |
| 2022 Q4 | -569.31 Thousand USD | 85.06% |
| 2021 Q3 | 451.26 Thousand USD | 120.14% |
| 2021 FY | - USD | -1962.73% |
| 2021 Q4 | -368.64 Thousand USD | -181.69% |
| 2021 Q2 | -2.24 Million USD | 36.92% |
| 2021 Q1 | -3.55 Million USD | -140.53% |
| 2020 Q2 | -4.44 Million USD | -37.35% |
| 2020 Q3 | -703.27 Thousand USD | 84.16% |
| 2020 FY | - USD | 107.31% |
| 2020 Q1 | -3.23 Million USD | -20.97% |
| 2020 Q4 | 8.76 Million USD | 1345.88% |
| 2019 FY | - USD | 36.42% |
| 2019 Q1 | -2.29 Million USD | 17.51% |
| 2019 Q2 | -4.87 Million USD | -112.35% |
| 2019 Q3 | -3.44 Million USD | 29.4% |
| 2019 Q4 | -2.67 Million USD | 22.42% |
| 2018 FY | - USD | -0.5% |
| 2018 Q2 | -1.39 Million USD | 20.2% |
| 2018 Q1 | -1.74 Million USD | 38.91% |
| 2018 Q4 | -2.78 Million USD | -55.03% |
| 2018 Q3 | -1.79 Million USD | -29.25% |
| 2017 Q4 | -2.85 Million USD | -192.67% |
| 2017 FY | - USD | -19.11% |
| 2017 Q1 | -1.32 Million USD | -85.63% |
| 2017 Q3 | -974.25 Thousand USD | 61.43% |
| 2017 Q2 | -2.52 Million USD | -90.91% |
| 2016 Q4 | -712.84 Thousand USD | 31.15% |
| 2016 FY | - USD | -49.12% |
| 2016 Q3 | -1.03 Million USD | 59.24% |
| 2016 Q2 | -2.54 Million USD | -16.72% |
| 2016 Q1 | -2.17 Million USD | 3.09% |
| 2015 Q3 | -1.04 Million USD | -7.08% |
| 2015 Q2 | -976.96 Thousand USD | -1768.04% |
| 2015 Q1 | -52.29 Thousand USD | 97.55% |
| 2015 FY | - USD | 32.53% |
| 2015 Q4 | -2.24 Million USD | -114.67% |
| 2014 FY | - USD | 27.05% |
| 2014 Q4 | -2.13 Million USD | -121.11% |
| 2014 Q1 | -1.6 Million USD | 25.58% |
| 2014 Q2 | -1.7 Million USD | -6.48% |
| 2014 Q3 | -964.99 Thousand USD | 43.39% |
| 2013 Q3 | -3.61 Million USD | -270.31% |
| 2013 Q1 | -2.02 Million USD | -31.1% |
| 2013 Q4 | -2.15 Million USD | 40.54% |
| 2013 Q2 | -976.96 Thousand USD | 51.76% |
| 2013 FY | - USD | -22.63% |
| 2012 Q3 | -2.85 Million USD | -35.4% |
| 2012 Q4 | -1.54 Million USD | 45.81% |
| 2012 FY | - USD | -74.51% |
| 2012 Q2 | -2.1 Million USD | -219.43% |
| 2012 Q1 | -659.03 Thousand USD | 75.58% |
| 2011 Q1 | -423.66 Thousand USD | -163.34% |
| 2011 Q3 | -615.47 Thousand USD | -19.33% |
| 2011 Q4 | -2.69 Million USD | -338.43% |
| 2011 FY | - USD | -240.95% |
| 2011 Q2 | -515.77 Thousand USD | -21.74% |
| 2010 FY | - USD | 41.9% |
| 2010 Q3 | -821.39 Thousand USD | -49.24% |
| 2010 Q4 | 668.88 Thousand USD | 181.43% |
| 2010 Q2 | -550.39 Thousand USD | 35.18% |
| 2010 Q1 | -849.16 Thousand USD | -335.32% |
| 2009 Q4 | 360.84 Thousand USD | 148.69% |
| 2009 FY | - USD | -23.81% |
| 2009 Q3 | -741.18 Thousand USD | 3.99% |
| 2009 Q2 | -771.97 Thousand USD | -56.63% |
| 2009 Q1 | -492.87 Thousand USD | 32.38% |
| 2008 FY | - USD | 0.0% |
| 2008 Q3 | -443.4 Thousand USD | 0.0% |
| 2008 Q4 | -728.84 Thousand USD | -64.38% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Akoya Biosciences, Inc. | -45.63 Million USD | 71.112% |
| AngioDynamics, Inc. | -14.29 Million USD | 7.766% |
| AtriCure, Inc. | -8.1 Million USD | -62.56% |
| Avinger, Inc. | -16.34 Million USD | 19.356% |
| Azenta, Inc. | 55.15 Million USD | 123.902% |
| BioLife Solutions, Inc. | -45.23 Million USD | 70.861% |
| The Cooper Companies, Inc. | 882.8 Million USD | 101.493% |
| Daxor Corporation | 329.74 Thousand USD | 4097.699% |
| Ekso Bionics Holdings, Inc. | -13.19 Million USD | 0.121% |
| Femasys Inc. | -13.16 Million USD | -0.096% |
| GlucoTrack, Inc. | -7.09 Million USD | -85.898% |
| Harvard Bioscience, Inc. | 9.49 Million USD | 238.86% |
| Hologic, Inc. | 1.29 Billion USD | 101.017% |
| ICU Medical, Inc. | 307.69 Million USD | 104.284% |
| Intuitive Surgical, Inc. | 2.39 Billion USD | 100.551% |
| KORU Medical Systems, Inc. | -9.39 Million USD | -40.24% |
| LeMaitre Vascular, Inc. | 48.99 Million USD | 126.908% |
| Innovative Eyewear, Inc. | -6.57 Million USD | -100.483% |
| Innovative Eyewear, Inc. | -6.57 Million USD | -100.483% |
| Masimo Corporation | 236.7 Million USD | 105.569% |
| Microbot Medical Inc. | -10.63 Million USD | -23.961% |
| Meihua International Medical Technologies Co., Ltd. | 15.77 Million USD | 183.586% |
| Merit Medical Systems, Inc. | 231.44 Million USD | 105.696% |
| Nephros, Inc. | -1.37 Million USD | -855.911% |
| NovoCure Limited | -175.86 Million USD | 92.504% |
| NEXGEL, Inc. | -2.73 Million USD | -382.858% |
| NEXGEL, Inc. | -2.73 Million USD | -382.858% |
| Singular Genomics Systems, Inc. | -86.49 Million USD | 84.76% |
| OraSure Technologies, Inc. | 76.15 Million USD | 117.309% |
| Pro-Dex, Inc. | 8.33 Million USD | 258.19% |
| Pulse Biosciences, Inc. | -42.36 Million USD | 68.886% |
| Precision Optics Corporation, Inc. | -2.51 Million USD | -424.772% |
| QuidelOrtho Corporation | 545.6 Million USD | 102.416% |
| Repligen Corporation | 124.29 Million USD | 110.606% |
| Sanara MedTech Inc. | -289.09 Thousand USD | -4459.719% |
| STAAR Surgical Company | 33.22 Million USD | 139.68% |
| Sharps Technology, Inc. | -8.98 Million USD | -46.787% |
| Utah Medical Products, Inc. | 24.8 Million USD | 153.143% |
| DENTSPLY SIRONA Inc. | 232 Million USD | 105.682% |
| Jin Medical International Ltd. | 3.44 Million USD | 482.877% |